WO2002026226A1 - Composition pharmaceutique contenant de la dihydroartemisinine indiquee pour le traitement de la malaria - Google Patents

Composition pharmaceutique contenant de la dihydroartemisinine indiquee pour le traitement de la malaria Download PDF

Info

Publication number
WO2002026226A1
WO2002026226A1 PCT/CN2001/000884 CN0100884W WO0226226A1 WO 2002026226 A1 WO2002026226 A1 WO 2002026226A1 CN 0100884 W CN0100884 W CN 0100884W WO 0226226 A1 WO0226226 A1 WO 0226226A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroartemisinin
salts
analogs
malaria
trimethoprim
Prior art date
Application number
PCT/CN2001/000884
Other languages
English (en)
Chinese (zh)
Inventor
Guoqiao Li
Original Assignee
Chongqing Kincare Medicinal Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4582950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002026226(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chongqing Kincare Medicinal Development Co., Ltd. filed Critical Chongqing Kincare Medicinal Development Co., Ltd.
Priority to AU2001289506A priority Critical patent/AU2001289506A1/en
Publication of WO2002026226A1 publication Critical patent/WO2002026226A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a hydroartemisinin pharmaceutical composition for treating and preventing mammals, especially human malaria and other types of malaria.
  • Multidrug-resistant malaria is spreading globally, with Africa and Southeast Asia particularly severe.
  • the World Health Organization has included "malaria control" as one of the important plans for the 21st century.
  • Mefloquine and its complex method Simimef.
  • a technical compound artemether (composed of artemether and phenethyl alcohol) purchased by Swiss NORVATIS pharmaceutical company from China may be better than existing antimalarial drugs, but its treatment still takes 3 days and is relatively costly.
  • Malarone which is being developed by Glaxo Wellcome in the United Kingdom, is composed of naphthoquinone and cyclochloroguanidine. There is no fast-acting drug in its formula. The course of treatment is 3 days, twice a day, and the cost is high. If the dosage is changed to once a day, nausea and vomiting have serious side effects.
  • the object of the present invention is to provide a new dihydroartemisinin pharmaceutical composition for fast-acting, high-efficiency, low-toxicity and short-course treatment of malaria, especially multi-drug-resistant malaria.
  • composition of the present invention contains (1) dihydroartemisinin as a therapeutically active ingredient
  • composition of the present invention further contains (3) trimethoprim (Trimethoprim), and / or its analogs and salts as a therapeutically active ingredient.
  • the content of the active ingredients is such that their combination is effective for treating malaria.
  • the ratio of each active ingredient in the composition of the present invention is as follows:
  • the medicine of the present invention may also be a compatible preparation of dihydroartemisinin and piperazine.
  • the weight (parts) ratio is:
  • the analogs of dihydroartemisinin in the composition of the present invention are artemisinin and its derivatives, such as artemisinin, artesunate, artemether, and arteether. Such drugs are eventually converted into dihydroartemisinin in the body and exert their killing effect on malaria.
  • Analogues of piperquine in the composition of the present invention include: 4-aminoquinoline derivatives such as chloroquine (Chloroquine), aminophenol 1 : (Amodiaquine), and the like.
  • Analogs of trimethoprim in the composition of the present invention include: Co-Trimoxazole / Bactrim and the like.
  • the salt of the active ingredient according to the present invention refers to a non-toxic base salt formed by an acidic compound and a pharmaceutically acceptable base, or a non-toxic acid addition salt formed by a basic compound and a pharmaceutically acceptable acid.
  • the non-toxic base salts include, but are not limited to, from pharmaceutically acceptable cations such as Alkali metal cations (such as potassium and sodium) and alkaline earth metal cations (such as calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine (glucamine) and lower alkanolammonium derived salts And other pharmaceutically acceptable organic amines.
  • the non-toxic acid addition salt refers to a non-toxic acid addition salt formed by a compound and an organic or inorganic acid.
  • salts containing pharmacologically acceptable anions such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate , Citrate, acid citrate, tartrate, tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, mesylate Salts, ethanesulfonic acid salts, benzoic acid salts, p-toluenesulfonate and naphthenate.
  • pharmacologically acceptable anions such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate , Citrate, acid citrate, tartrate, tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, mesylate Salts, ethanes
  • Dihydroartemisinin has Fast-acting, low-toxicity, can quickly and massively kill the drug-resistant P.
  • the drug of the present invention has undergone pharmacodynamics, toxicology, general pharmacological tests and clinical research, as well as preparation technology, quality testing and stability investigation, etc., and has curative effects on malaria in China's Hainan province and Vietnam, Thailand, and Cambodia in areas where drug-resistant malaria is endemic. experimenting. The results of the study prove that its efficacy on malaria, especially multi-drug-resistant malaria, is superior to any existing anti-malarial drugs. It can be used to treat malaria, psoriatic malaria, and other types of malaria. It is by far the world's highest cure rate for malaria , New insecticide with fast insecticidal speed, low toxicity and side reaction, high safety, single process cartridge, mature and good stability.
  • Piperazine used in the existing treatment methods is usually used in its phosphate form, and one of the main components of the composition of the present invention can also be used without its phosphate form, which reduces the dosage, reduces side effects, and reduces costs. .
  • the biggest feature of the composition of the present invention is that Then, it only takes 2 days to cure. The actual application value is great.
  • the pharmaceutical preparation of the present invention refers to the above-mentioned hydroartemisinin, piperquine and the like, and the salts thereof, with or without trimethoprim as a synergist according to different therapeutic uses, and controlling each active ingredient in the Within the specified ratio range, combined with known pharmaceutical preparation technology and acceptable excipients or carrier substances at the pharmaceutical level, it is made into a solid by the usual known preparation production methods such as pulverization, mixing, dissolving, tabletting and coating. Or liquid preparations, such as tablets, capsules, granules, suppositories and injections.
  • the pharmaceutically acceptable carrier according to the present invention refers to a pharmaceutically acceptable carrier that does not affect the activity of each active ingredient and has no toxic or side effects on the human body.
  • the composition of the present invention can be formulated for oral administration, such as an emotional diluent or an assimilated edible carrier, or it can be encapsulated in a hard or soft shell capsule, or it can be compressed into tablets.
  • the active compound can be combined with excipients in ingestible tablets, pills, buccal tablets, granules, dragees, capsules, tinctures, suppositories, syrups, Glutinous rice paper tincture and other dosage forms are used.
  • Such compositions and preparations should contain at least 1% by weight of active compound.
  • an oral unit dosage form contains from about 50 mg to about 1000 mg of the active compound.
  • Tablets, lozenges, pills, capsules, etc. may also contain the following components: a binder, such as gum, gum arabic, corn starch, or gelatin; an excipient, such as dicalcium tablet, a disintegrant, such as corn Starch, potato starch, alginic acid, etc .; lubricants, such as magnesium stearate; sweeteners, such as sucrose, lactose, or saccharin, or flavoring agents, such as mint, holly oil, or cherry pick flavoring agents.
  • a binder such as gum, gum arabic, corn starch, or gelatin
  • an excipient such as dicalcium tablet, a disintegrant, such as corn Starch, potato starch, alginic acid, etc .
  • lubricants such as magnesium stearate
  • sweeteners such as sucrose, lactose, or saccharin
  • flavoring agents such as mint, holly oil, or cherry pick flavoring agents.
  • the unit dosage form is a
  • tablets, pills or capsules can be coated with shellac, sugar or both.
  • Syrups or tinctures can contain Active compounds also contain sucrose as a sweetener, methyl paraben and propyl ester as preservatives, and dyes and flavoring agents such as cherry pickle or orange flavoring agents.
  • Any raw material used to prepare any unit dosage form should be pharmaceutically pure and substantially non-toxic at the dosages used.
  • the active compound may be incorporated in a sustained-release preparation.
  • compositions suitable for injection use include sterile aqueous solutions (as long as they are water soluble) and sterile powders for the temporary preparation of sterile injectable solutions. They must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium, for example, containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils.
  • polyol for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.
  • suitable mixtures thereof and vegetable oils.
  • the use of various antibacterial and antifungal agents can prevent the effects of microorganisms, such as parabens, chlorobutanol, phenol, sorbitol, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugar
  • Sterile injectable solutions are prepared by mixing the required amount of various active compounds in a suitable solvent with a variety of other ingredients listed above, and then sterilizing by filtration or other appropriate means, if necessary .
  • Dispersions are also targeted by the present invention. They can be prepared by incorporating a variety of sterile active ingredients into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred method of preparation includes vacuum drying and freeze drying techniques to obtain a powder of the active ingredient plus any additional required ingredients, the additional ingredients from the previous sterile filtration The solution.
  • Pharmaceutically acceptable carriers and / or diluents include any of all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • the use of these media and agents for pharmaceutically active substances is well known in the art. Except incompatible with the active ingredient within the scope of conventional media or agents, the present invention is directed to its use in therapeutic compositions.
  • unit dosage forms for oral compositions for easy administration and uniform dosage.
  • the unit dosage form used herein refers to physically discrete units, suitable as A single dose is used for treatment; each unit contains a predetermined amount of active substance associated with the desired pharmaceutical carrier, and the content is calculated to produce the desired therapeutic effect.
  • the description of the unit dosage form of the present invention depends on and directly depends on (a) the unique properties of the active substance and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the field of formulation.
  • the effective amount targeted by the present invention will vary depending on the severity of the disease and the health condition and age of the subject. Factors such as the size of the active ingredient used, the dosage form and the route of administration should also be considered. Generally, the composition of the present invention is administered at 20 mg-300 mg (the other active ingredient is calculated according to the aforementioned ratio) based on hydroartemisinin every day, and the effect can be seen in 2 days.
  • the pharmacodynamic research on rat malaria and monkey malaria has shown that the dihydroartemisinin composition of the present invention has significant synergistic effects.
  • Treatment of 975 cases of falciparum malaria, follow-up observation for 28 days, cure rate of 96.9%, relapse rate of 3.1%, treatment of 171 cases of vivax malaria, same follow-up observation of 28 days, recurrence rate of 2.7%, can quickly control clinical symptoms.
  • the average antipyretic time is 16-25 hours, and the average protozoan time is 24-56 hours.
  • the dose of hydrogen artemisinin can kill more than 95% of Plasmodium falciparum in 24 hours.
  • Random comparisons with the dihydroartemisinin composition of Example 1 include: mefloquine 1250mg, cure rate 82.5%; Fansimef 3 tablets, cure rate 82.9%; artesunate 600mg / 5 days, cure rate 66.2%; A Fluoroquine 750mg + artesunate 150mg, the cure rate was 70.7%.
  • the present invention also uses hydroartemisinin, piperazine and the composition of the present invention to compare the therapeutic effects, and the results are as follows: Table 1: Clinical comparison results of the dihydroartemisinin composition of the present invention with dihydroartemisinin and piperazine
  • Example 1 Production of 1000 tablets of the drug of the present invention, the amount of which was measured according to the following formula: Dihydroartemisinin 75g
  • the raw and auxiliary materials are tested first, and after crushing and passing through a 100-mesh sieve, the components are accurately measured according to the formula, and the components are mixed and uniformly granulated, tabletted, and packed.
  • the method and dosage of the drug in this embodiment One course of treatment for an adult is 2 days, and the total dose of the course of treatment is 300 mg of dihydroartemisinin, 1.5 g of piperazine, and 750 mg of trimethoprim.
  • the administration method is 0 hours, 8 hours, 24 hours, and 32 hours, 1 tablet each time (ie, dihydroartemisinin 75 mg, piperazine 375 mg, and trimethoprim 187.5 mg). After more than 500 clinical trials It proves that this drug has the characteristics of fast-acting, high-efficiency, low-toxicity and short course of treatment, and its efficacy is obviously better than similar drugs at home and abroad.
  • Example 2 To produce 1000 tablets of the drug of the present invention, take the following formula:
  • Example 3 Formula for producing 1000 bags of compound dihydroartemisinin granules:
  • each suppository contains 85 mg of dihydroartemisinin, 500 mg of piperazine phosphate, and 160 mg of trimethoprim for rectal administration, 1 capsule 2 times a day. 4 capsules per course.
  • Example 5 Formulation example of the injection of the present invention, made into 1000 succinate piperazine injections:
  • Example 6 According to the ointment formulation of the present invention for rectal administration of children, 1000 compound dihydroartemisinin ointments were prepared according to the usual process of ointment:
  • Each ointment contains 50mg dihydroartemisinin, 250mg piperazine, and 140mg trimethoprim, twice a day, one at a time for two days.
  • the invention provides a dihydroartemisinin composition for treating malaria, which can be used for preparing a pharmaceutical preparation for treating malaria.
  • Animal tests and clinical tests have shown that the composition of the present invention has the characteristics of fast-acting, high-efficiency, low cost, low toxicity, short treatment course, and its curative effect and low toxicity and side effects are obviously better than similar products at home and abroad.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant de la dihydroartémisinine indiquée pour le traitement de la malaria. La composition pharmaceutique faisant l'objet de cette invention contient de la dihydroartémisinine, de la pipérazine, du triméthoprime et d'autres sels et composés. Elle a fait ses preuves lors de tests effectués sur les animaux et lors de son utilisation clinique et présente les avantages suivants : effet rapide, bonne efficacité, toxicité négligeable et courte durée de traitement. Par ailleurs, les effets secondaires liés à la toxicité sont nettement améliorés par rapport aux médicaments du même type utilisés de nos jours en Chine et à l'étranger. L'invention concerne également deux composés principaux, à savoir la dihydroartémisinine et la pipérazine qui sont mélangées et, de ce fait, donnent des résultats remarquables.
PCT/CN2001/000884 2000-08-23 2001-05-31 Composition pharmaceutique contenant de la dihydroartemisinine indiquee pour le traitement de la malaria WO2002026226A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289506A AU2001289506A1 (en) 2000-08-23 2001-05-31 Pharmaceutical composition of dihydroartemisinin for treating malaria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00113134.6 2000-08-23
CNB001131346A CN1135974C (zh) 2000-08-23 2000-08-23 抗疟药新药复方双氢青蒿素

Publications (1)

Publication Number Publication Date
WO2002026226A1 true WO2002026226A1 (fr) 2002-04-04

Family

ID=4582950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000884 WO2002026226A1 (fr) 2000-08-23 2001-05-31 Composition pharmaceutique contenant de la dihydroartemisinine indiquee pour le traitement de la malaria

Country Status (3)

Country Link
CN (1) CN1135974C (fr)
AU (1) AU2001289506A1 (fr)
WO (1) WO2002026226A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132438A2 (fr) * 2006-05-17 2007-11-22 Ranbaxy Laboratories Limited Traitement antipaludéen faisant appel à une combinaison d'un dérivé d'artémisinine synthétique et d'un dérivé de bisquinoline
US7842719B2 (en) 2002-10-31 2010-11-30 Kemin Foods, L.C. Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
US7851512B2 (en) 2003-09-26 2010-12-14 Li Guogiao Composition containing artemisinin for treatment of malaria

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1833644B (zh) * 2005-03-18 2010-07-21 中国人民解放军第三军医大学 青蒿素及其衍生物二氢青蒿素、蒿甲醚、蒿乙醚、青蒿琥酯在制药中的应用
CN107929240A (zh) * 2017-12-13 2018-04-20 桂林南药股份有限公司 磷酸哌喹口服液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219865A (en) * 1987-05-08 1993-06-15 Hoechst Aktiengesellschaft Pharmaceutical combination for the prophylaxis and therapy of malaria
WO1999025351A1 (fr) * 1997-11-18 1999-05-27 Guangzhou Kincare Technology Corp. Compositions pharmaceutiques antipaludiques
CN1237416A (zh) * 1998-06-02 1999-12-08 广州市健桥医药科技进出口有限公司 复方哌喹片

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219865A (en) * 1987-05-08 1993-06-15 Hoechst Aktiengesellschaft Pharmaceutical combination for the prophylaxis and therapy of malaria
WO1999025351A1 (fr) * 1997-11-18 1999-05-27 Guangzhou Kincare Technology Corp. Compositions pharmaceutiques antipaludiques
CN1237416A (zh) * 1998-06-02 1999-12-08 广州市健桥医药科技进出口有限公司 复方哌喹片

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842719B2 (en) 2002-10-31 2010-11-30 Kemin Foods, L.C. Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
US7851512B2 (en) 2003-09-26 2010-12-14 Li Guogiao Composition containing artemisinin for treatment of malaria
WO2007132438A2 (fr) * 2006-05-17 2007-11-22 Ranbaxy Laboratories Limited Traitement antipaludéen faisant appel à une combinaison d'un dérivé d'artémisinine synthétique et d'un dérivé de bisquinoline
WO2007132438A3 (fr) * 2006-05-17 2008-01-24 Ranbaxy Lab Ltd Traitement antipaludéen faisant appel à une combinaison d'un dérivé d'artémisinine synthétique et d'un dérivé de bisquinoline

Also Published As

Publication number Publication date
AU2001289506A1 (en) 2002-04-08
CN1305810A (zh) 2001-08-01
CN1135974C (zh) 2004-01-28

Similar Documents

Publication Publication Date Title
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
US6287597B1 (en) Antihistaminic/decongestant compositions
US6017932A (en) Pharmaceutical compositions containing at least one NSAID having increased bioavailability
KR100221689B1 (ko) 항말라리아조성물
US20040234593A1 (en) Diphenhydramine tannate compositions and methods of use
KR20010075021A (ko) 불법적 용도로서 부적합한 교감신경흥분성 아민 염을포함하는 조성물
US20110300137A1 (en) Use of lumefantrine and related compounds in the treatment of cancer
BRPI0610851A2 (pt) associação entre a ferroquina e um derivado de artemisinina, composição farmacêutica, utilização da referida associação e kit
US11883376B2 (en) Viral infection treatment with 5-aminolevulinic acid
JP2769696B2 (ja) 月経困難症及び／又は月経前症候群の軽減用薬剤組成物とその調製法
JP7243876B2 (ja) 固形製剤
WO2005034936A1 (fr) Utilisation de l-butylphtalide dans la fabrication de medicaments destines a la prevention et au traitement de l'infarctus cerebral
AU2003296647A1 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US20060269598A1 (en) Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use
WO2002026226A1 (fr) Composition pharmaceutique contenant de la dihydroartemisinine indiquee pour le traitement de la malaria
JP4377564B2 (ja) 内服用組成物
US20140011830A1 (en) Artemisinin-Based Combination Therapy For Treating Parasitic Mediated Disease
WO2015041722A1 (fr) Traitement combiné amélioré à base d'artémisinine permettant de traiter une maladie à médiation par des parasites
US20050069584A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
JP3560970B2 (ja) ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物
US20060269597A1 (en) Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions
CZ79593A3 (en) Antitussive preparation
US20070248667A1 (en) Tannate Compositions and Methods of Use
EP0935964A1 (fr) Compositions pharmaceutiques contenant des anti-inflammatoires non steroidiens et de la piperine
EP2322244B1 (fr) Composition pharmaceutique à base d'artesunate, de sulfaméthoxypyrazine et de pyriméthamine permettant le traitement du palludisme en un jour, sous forme de comprimé

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP